Terms: = Colorectal cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
9 results:
1. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
[TBL] [Abstract] [Full Text] [Related]
2. Sequential Administration of xpo1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated colorectal cancer.
Inoue A; Robinson FS; Minelli R; Tomihara H; Rizi BS; Rose JL; Kodama T; Srinivasan S; Harris AL; Zuniga AM; Mullinax RA; Ma X; Seth S; Daniele JR; Peoples MD; Loponte S; Akdemir KC; Khor TO; Feng N; Roszik J; Sobieski MM; Brunell D; Stephan C; Giuliani V; Deem AK; Shingu T; Deribe YL; Menter DG; Heffernan TP; Viale A; Bristow CA; Kopetz S; Draetta GF; Genovese G; Carugo A
Gastroenterology; 2021 Jul; 161(1):196-210. PubMed ID: 33745946
[TBL] [Abstract] [Full Text] [Related]
3. Association of xpo1 Overexpression with NF-κB and Ki67 in colorectal cancer.
Aladhraei M; Kassem Al-Thobhani A; Poungvarin N; Suwannalert P
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3747-3754. PubMed ID: 31870117
[TBL] [Abstract] [Full Text] [Related]
4. Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of colorectal cancer to Proteasome Inhibitor.
Wu T; Chen W; Zhong Y; Hou X; Fang S; Liu CY; Wang G; Yu T; Huang YY; Ouyang X; Li HQ; Cui L; Yang Y
Mol Cancer Ther; 2017 Apr; 16(4):717-728. PubMed ID: 27903750
[TBL] [Abstract] [Full Text] [Related]
5. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
[TBL] [Abstract] [Full Text] [Related]
6. xpo1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal cancer.
Ferreiro-Neira I; Torres NE; Liesenfeld LF; Chan CH; Penson T; Landesman Y; Senapedis W; Shacham S; Hong TS; Cusack JC
Clin Cancer Res; 2016 Apr; 22(7):1663-73. PubMed ID: 26603256
[TBL] [Abstract] [Full Text] [Related]
7. Novel reversible selective inhibitor of nuclear export shows that crm1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract] [Full Text] [Related]
8. Redefining the subcellular location and transport of APC: new insights using a panel of antibodies.
Brocardo M; Näthke IS; Henderson BR
EMBO Rep; 2005 Feb; 6(2):184-90. PubMed ID: 15678162
[TBL] [Abstract] [Full Text] [Related]
9. Suppressor of fused negatively regulates beta-catenin signaling.
Meng X; Poon R; Zhang X; Cheah A; Ding Q; Hui CC; Alman B
J Biol Chem; 2001 Oct; 276(43):40113-9. PubMed ID: 11477086
[TBL] [Abstract] [Full Text] [Related]
